Terms: = Head and neck cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Treatment
39 results:
1. cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to fgfr2.
Liu F; Tang L; Liu H; Chen Y; Xiao T; Gu W; Yang H; Wang H; Chen P
Cell Death Dis; 2024 Apr; 15(4):279. PubMed ID: 38637504
[TBL] [Abstract] [Full Text] [Related]
2. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
3. Patterns of treatment Failure After Selective Rearranged During Transfection (RET) Inhibitors in Patients With Metastatic Medullary Thyroid Carcinoma.
Hadoux J; Al Ghuzlan A; Lamartina L; Bani MA; Moog S; Attard M; Scoazec JY; Hartl D; Aldea M; Friboulet L; Jules-Clement G; Italiano A; Besse B; Lacroix L; Baudin E
JCO Precis Oncol; 2023 Sep; 7():e2300053. PubMed ID: 38127829
[TBL] [Abstract] [Full Text] [Related]
4. FGFR1/2/3-rearranged carcinoma of the head and neck: expanded histological spectrum crossing path with high-risk HPV in the sinonasal tract.
Chu YH; Mullaney K; DiNapoli SE; Cohen MA; Xu B; Ghossein R; Katabi N; Dogan S
Histopathology; 2024 Mar; 84(4):589-600. PubMed ID: 38010295
[TBL] [Abstract] [Full Text] [Related]
5. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
6. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the treatment of FGFR-Aberrant Tumors.
Javle M; King G; Spencer K; Borad MJ
Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
[TBL] [Abstract] [Full Text] [Related]
7. The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal cancers.
Lee MS; Kaseb AO; Pant S
Clin Cancer Res; 2023 Sep; 29(17):3267-3274. PubMed ID: 37092904
[TBL] [Abstract] [Full Text] [Related]
8. fgfr2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract.
Albin J; Fahrig L; Siemanowski J; Rehkaemper J; Gebauer F; Zander T; Buettner R; Bruns CJ; Schroeder W; Alakus H; Hieggelke L; Quaas A
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5289-5300. PubMed ID: 36416959
[TBL] [Abstract] [Full Text] [Related]
9. Identification and characterization of fgfr2
Qiu H; Zhang X; Qi J; Zhang J; Tong Y; Li L; Fu L; Qin YR; Guan X; Zhang L
J Exp Clin Cancer Res; 2022 Aug; 41(1):240. PubMed ID: 35941662
[TBL] [Abstract] [Full Text] [Related]
10. Precision medicine: Sustained response to erdafitinib in fgfr2-mutant, multiply recurrent ameloblastoma.
Lawson-Michod KA; Le CH; Tranesh G; Thomas PC; Bauman JE
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1656. PubMed ID: 35761436
[TBL] [Abstract] [Full Text] [Related]
11. Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies.
Kleo K; Jovanovic VM; Arndold A; Lehmann A; Lammert H; Berg E; Harloff H; Treese C; Hummel M; Daum S
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1049-1061. PubMed ID: 35246724
[TBL] [Abstract] [Full Text] [Related]
12. AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer.
Aytatli A; Barlak N; Sanli F; Caglar HO; Gundogdu B; Tatar A; Ittmann M; Karatas OF
Cell Oncol (Dordr); 2022 Feb; 45(1):41-56. PubMed ID: 34837170
[TBL] [Abstract] [Full Text] [Related]
13. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
Meric-Bernstam F; Bahleda R; Hierro C; Sanson M; Bridgewater J; Arkenau HT; Tran B; Kelley RK; Park JO; Javle M; He Y; Benhadji KA; Goyal L
Cancer Discov; 2022 Feb; 12(2):402-415. PubMed ID: 34551969
[TBL] [Abstract] [Full Text] [Related]
14. Can Ultrasound in Combination with Virtual Touch Imaging Quantification Predict the Dignity of a Parotid Tumor?
Jering M; Zenk J; Thölken R; Rüger H; Psychogios G
Ultrasound Med Biol; 2021 May; 47(5):1192-1203. PubMed ID: 33541749
[TBL] [Abstract] [Full Text] [Related]
15. Revisiting MET: Clinical Characteristics and treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric cancers.
Chaudhary SP; Kwak EL; Hwang KL; Lennerz JK; Corcoran RB; Heist RS; Russo AL; Parikh A; Borger DR; Blaszkowsky LS; Faris JE; Murphy JE; Azzoli CG; Roeland EJ; Goyal L; Allen J; Mullen JT; Ryan DP; Iafrate AJ; Klempner SJ; Clark JW; Hong TS
Oncologist; 2020 Nov; 25(11):e1691-e1700. PubMed ID: 32820577
[TBL] [Abstract] [Full Text] [Related]
16. The Integrated Analyses of Driver Genes Identify Key Biomarkers in Thyroid cancer.
Xu Q; Song A; Xie Q
Technol Cancer Res Treat; 2020; 19():1533033820940440. PubMed ID: 32812852
[TBL] [Abstract] [Full Text] [Related]
17. A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer.
Goyal L; Chaudhary SP; Kwak EL; Abrams TA; Carpenter AN; Wolpin BM; Wadlow RC; Allen JN; Heist R; McCleary NJ; Chan JA; Goessling W; Schrag D; Ng K; Enzinger PC; Ryan DP; Clark JW
Invest New Drugs; 2020 Oct; 38(5):1533-1539. PubMed ID: 31898183
[TBL] [Abstract] [Full Text] [Related]
18. Fibroblast growth factor receptor promotes progression of cutaneous squamous cell carcinoma.
Khandelwal AR; Kent B; Hillary S; Alam MM; Ma X; Gu X; DiGiovanni J; Nathan CO
Mol Carcinog; 2019 Oct; 58(10):1715-1725. PubMed ID: 31254372
[TBL] [Abstract] [Full Text] [Related]
19. The efficacy of cisplatin on nasopharyngeal carcinoma cells may be increased via the downregulation of fibroblast growth factor receptor 2.
Pu L; Su L; Kang X
Int J Mol Med; 2019 Jul; 44(1):57-66. PubMed ID: 31115494
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric cancer.
Won E; Basunia A; Chatila WK; Hechtman JF; Chou JF; Ku GY; Chalasani SB; Boyar MS; Goldberg Z; Desai AM; Tuvy Y; Berger MF; Tang L; Kelsen DP; Schattner M; Ilson DH; Capanu M; Solit DB; Schultz N; Janjigian YY
Clin Cancer Res; 2019 Jul; 25(13):3811-3817. PubMed ID: 30952642
[TBL] [Abstract] [Full Text] [Related]
[Next]